Wiener Wissenschafts-, Forschungs- und Technologiefonds Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2010
NCT01102101
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

WWTF, Wiener Wissenschafts-, Forschungs- und Technologiefonds

Active Ingredients

Drugs in Phase 3 Trials (1)

remifentanil (ultiva) (1 trial)

Drugs in Other Trials (2)

glucose (1 trial)

nevulose (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neuralgia (Phase 3)

Neuralgia, Postherpetic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3